Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The NOD-like receptor family, pyrin-domain-containing-3 (NLRP3) inflammasome is a key regulator within the tumor microenvironment (TME).
• Tumor-intrinsic NLRP3 inflammasome activation has been linked to pro-tumorigenic mechanisms and immunosuppression.
• Emerging research highlights its role in adaptive resistance to anti-PD-1 immunotherapy via heat shock protein-70 (HSP70) release.

Purpose of the Study:

• To elucidate the role of the tumor NLRP3 inflammasome in regulating anti-tumor immunity and immunotherapy resistance.
• To investigate the impact of genetic alterations in the NLRP3 signaling axis on T cell-mediated tumor cell killing.
• To identify the NLRP3 inflammasome and HSP70 as potential therapeutic targets for enhancing anti-PD-1 immunotherapy.

Main Methods:

• Analysis of genetic alterations influencing the NLRP3 signaling axis.
• Investigation of NLRP3 inflammasome activation and downstream HSP70 release in the TME.
• Assessment of T cell-mediated tumor cell killing in relation to NLRP3 pathway activity.

Main Results:

• The tumor NLRP3 inflammasome and secreted HSP70 regulate anti-tumor immunity.
• NLRP3 pathway activity influences adaptive resistance to anti-PD-1 immunotherapy.
• Genetic alterations in NLRP3 signaling impact T cell cytotoxicity and immune escape.

Conclusions:

• The NLRP3 inflammasome and HSP70 are promising targets for modulating the TME and improving anti-PD-1 responses.
• Targeting NLRP3 could enhance anti-tumor immunity and overcome resistance to checkpoint inhibitor immunotherapy.
• Further research into tumor-specific NLRP3 regulation is crucial for developing effective, targeted therapeutic strategies.